SEATTLE, WASHINGTON--(Marketwired - April 27, 2015) - Ventripoint Diagnostics Ltd. ("Ventripoint") (TSX VENTURE:VPT) announces that a group led by Dr. Daniel Knight in London, United Kingdom, has demonstrated further the accuracy of Ventripoint's VMS™ heart analysis system.
"This clinical study demonstrates that the VMS analysis of the right heart is reproducible between operators", stated Jim Bodtke, Vice President of Clinical Affairs for Ventripoint. "This means that the cardiologist can trust previous test results regardless of the examiner, so long as the echocardiagram was analyzed using the VMS. Further, the study determined that results produced by VMS were more accurate and reproducible than Fractional-Area Change, which is one of the methods of estimating right-heart function recommended by the ASE guidelines." The imaging guidelines, published by the American Society of Echocardiography (ASE) in the Journal of the ASE, are written by experts in the field of echocardiography and cardiology, and provide a recommended standard of care.
Dr. George Adams, President and CEO of Ventripoint added, "It's great to have confirmation from this study showing the VMS analysis to be superior to current techniques that analyze right heart function."
The study design compared the accuracy of the measurements performed by the cardiologists who independently performed an echocardiogram on the same patient and then analyzed the scans. This "test-retest" design is unique in that a majority of studies comparing measurements performed by different individuals are typically completed with the observers using the same echocardiographical images. This type of study method reflects the real world clinical use of echocardiography, where patients receive echocardiograms on different days performed by different cardiologists and they are used to assess if changes in heart function have occurred. An accurate, reproducible procedure is absolutely necessary to make therapeutic decisions.
The paper has been accepted for publication in the Journal of the American Society of Echocardiography and is titled "Accuracy and Test-Retest Reproducibility of Two-Dimensional Knowledge-Based Volumetric Reconstruction of the Right Ventricle in Pulmonary Hypertension". The full article is available at http://www.onlinejase.com/article/S0894-7317%2815%2900142-X/references.
About the Journal of the American Society of Echocardiography
The Journal of the American Society of Echocardiography, with a monthly print and digital distribution of over 50,000, is considered the top-tier publication for peer-reviewed studies related to cardiac ultrasound imaging.
About Ventripoint Diagnostics Ltd.
Ventripoint has created tools to monitor patients with heart disease, a leading cause of death in developed countries. VMS™ is the first cost-effective and accurate tool for measuring right ventricle heart function. The Corporation has a suite of applications for all major heart diseases and imaging modalities including congenital heart disease, left or right heart failure and normal hearts - a multi-billion dollar market potential.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS: The statements made in this news release that are not historical facts may contain forward-looking information that involves risk and uncertainties. All statements, other than statements of historical facts, which address Ventripoint's expectations, should be considered forward-looking statements. Such statements are based on management's exercise of business judgment as well as assumptions made by and information currently available to management. When used in this document, the words "may", "will", "anticipate", "believe", "estimate", "expect", "intend" and words of similar import, are intended to identify any forward-looking statements. You should not place undue reliance on these forward-looking statements. These statements reflect a current view of future events and are subject to certain risks and uncertainties as contained in the Corporation's filings with Canadian securities regulatory authorities. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results could differ materially from those anticipated in these forward-looking statements. A description of assumptions used to develop such forward-looking information and a description of risk factors that may cause actual results to differ materially from forward-looking information can be found in Ventripoint's disclosure documents on the SEDAR website at www.sedar.com. The Corporation undertakes no obligation, and does not intend, to update, revise or otherwise publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof, or to reflect the occurrence of any unanticipated events. Although management believes that expectations are based on reasonable assumptions, no assurance can be given that these expectations will materialize.